PL3495352T3 - Postacie krystaliczne antagonisty receptora androgenowego, ich sposób wytwarzania i zastosowanie - Google Patents
Postacie krystaliczne antagonisty receptora androgenowego, ich sposób wytwarzania i zastosowanieInfo
- Publication number
- PL3495352T3 PL3495352T3 PL17842980T PL17842980T PL3495352T3 PL 3495352 T3 PL3495352 T3 PL 3495352T3 PL 17842980 T PL17842980 T PL 17842980T PL 17842980 T PL17842980 T PL 17842980T PL 3495352 T3 PL3495352 T3 PL 3495352T3
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- receptor antagonist
- androgen receptor
- crystal forms
- crystal
- Prior art date
Links
- 229940123407 Androgen receptor antagonist Drugs 0.000 title 1
- 239000003936 androgen receptor antagonist Substances 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610737732 | 2016-08-26 | ||
| CN201610871736 | 2016-09-30 | ||
| CN201610876685 | 2016-10-08 | ||
| PCT/CN2017/099036 WO2018036558A1 (zh) | 2016-08-26 | 2017-08-25 | 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途 |
| EP17842980.9A EP3495352B1 (en) | 2016-08-26 | 2017-08-25 | Crystal forms of an androgen receptor antagonist, preparation method and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3495352T3 true PL3495352T3 (pl) | 2021-08-02 |
Family
ID=61246439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17842980T PL3495352T3 (pl) | 2016-08-26 | 2017-08-25 | Postacie krystaliczne antagonisty receptora androgenowego, ich sposób wytwarzania i zastosowanie |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10815221B2 (pl) |
| EP (1) | EP3495352B1 (pl) |
| JP (1) | JP6716023B2 (pl) |
| CN (1) | CN109641851B (pl) |
| CY (1) | CY1124083T1 (pl) |
| DK (1) | DK3495352T3 (pl) |
| ES (1) | ES2869882T3 (pl) |
| HR (1) | HRP20210667T1 (pl) |
| HU (1) | HUE053958T2 (pl) |
| LT (1) | LT3495352T (pl) |
| PL (1) | PL3495352T3 (pl) |
| PT (1) | PT3495352T (pl) |
| RS (1) | RS61773B1 (pl) |
| SI (1) | SI3495352T1 (pl) |
| SM (1) | SMT202100251T1 (pl) |
| WO (1) | WO2018036558A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250065940A (ko) * | 2017-03-07 | 2025-05-13 | 오리온 코포레이션 | 결정성 의약품의 제조 |
| CN116396220A (zh) | 2017-08-09 | 2023-07-07 | 杭州领业医药科技有限公司 | Odm-201晶型及其制备方法和药物组合物 |
| JP2021515040A (ja) * | 2018-02-27 | 2021-06-17 | サンド・アクチエンゲゼルシヤフト | ダロルタミドの結晶形態ｉｉ |
| JP2022505033A (ja) * | 2018-10-18 | 2022-01-14 | ジェムフィアー セラピューティクス インコーポレイテッド | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 |
| WO2022036782A1 (zh) * | 2020-08-18 | 2022-02-24 | 拜耳消费者护理股份有限公司 | 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途 |
| EP4486727B1 (en) | 2022-02-28 | 2026-02-25 | Química Sintética, S.A. | Crystalline form of darolutamide |
| CA3251059A1 (en) | 2022-05-02 | 2023-11-09 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions, systems and methods for modulating a target gene |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR078793A1 (es) * | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| JP5964407B2 (ja) * | 2011-04-21 | 2016-08-03 | オリオン コーポレーション | アンドロゲン受容体調節カルボキシアミド |
| HUE058986T2 (hu) * | 2015-01-30 | 2022-09-28 | Orion Corp | Egy karboxamid-származék és annak diasztereomerei stabil kristályformában |
| CN116396220A (zh) * | 2017-08-09 | 2023-07-07 | 杭州领业医药科技有限公司 | Odm-201晶型及其制备方法和药物组合物 |
-
2017
- 2017-08-25 HU HUE17842980A patent/HUE053958T2/hu unknown
- 2017-08-25 WO PCT/CN2017/099036 patent/WO2018036558A1/zh not_active Ceased
- 2017-08-25 EP EP17842980.9A patent/EP3495352B1/en active Active
- 2017-08-25 RS RS20210521A patent/RS61773B1/sr unknown
- 2017-08-25 PT PT178429809T patent/PT3495352T/pt unknown
- 2017-08-25 SI SI201730734T patent/SI3495352T1/sl unknown
- 2017-08-25 JP JP2019511530A patent/JP6716023B2/ja active Active
- 2017-08-25 ES ES17842980T patent/ES2869882T3/es active Active
- 2017-08-25 HR HRP20210667TT patent/HRP20210667T1/hr unknown
- 2017-08-25 CN CN201780048143.1A patent/CN109641851B/zh active Active
- 2017-08-25 DK DK17842980.9T patent/DK3495352T3/da active
- 2017-08-25 US US16/328,249 patent/US10815221B2/en active Active
- 2017-08-25 SM SM20210251T patent/SMT202100251T1/it unknown
- 2017-08-25 PL PL17842980T patent/PL3495352T3/pl unknown
- 2017-08-25 LT LTEP17842980.9T patent/LT3495352T/lt unknown
-
2021
- 2021-04-27 CY CY20211100367T patent/CY1124083T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SMT202100251T1 (it) | 2021-05-07 |
| DK3495352T3 (da) | 2021-05-03 |
| US20200239450A1 (en) | 2020-07-30 |
| CN109641851B (zh) | 2022-09-02 |
| CY1124083T1 (el) | 2022-03-24 |
| EP3495352B1 (en) | 2021-01-27 |
| PT3495352T (pt) | 2021-05-03 |
| HUE053958T2 (hu) | 2021-08-30 |
| JP6716023B2 (ja) | 2020-07-01 |
| EP3495352A1 (en) | 2019-06-12 |
| WO2018036558A1 (zh) | 2018-03-01 |
| LT3495352T (lt) | 2021-06-10 |
| JP2019526570A (ja) | 2019-09-19 |
| SI3495352T1 (sl) | 2021-08-31 |
| RS61773B1 (sr) | 2021-05-31 |
| HRP20210667T1 (hr) | 2021-05-28 |
| ES2869882T3 (es) | 2021-10-26 |
| CN109641851A (zh) | 2019-04-16 |
| US10815221B2 (en) | 2020-10-27 |
| EP3495352A4 (en) | 2019-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265806A (en) | Compounds and Methods for Targeted Reduction of Androgen Receptor | |
| SI3495352T1 (sl) | Kristalinične oblike antagonista androgenskih receptorjev, postopek njihove priprave in njihova uporaba | |
| SI3280441T1 (sl) | Protitelesa anti-sortilin in metoda njihove uporabe | |
| PT3470400T (pt) | Formas cristalinas de ozanimod e cloridrato de ozanimod, e processos para a preparação das mesmas | |
| EP3094346A4 (en) | Vista antagonist and methods of use | |
| ZA201706671B (en) | Process for the preparation of androgen receptor antagonists and intermediates thereof | |
| ZA201701216B (en) | Improved locking apparatus, locking member, and method of use | |
| IL284005A (en) | Glucocorticoid receptor inhibitors | |
| ZA201805496B (en) | Somatostatin receptor antagonist compounds and methods of using the same | |
| PT3216791T (pt) | Substância polimórfica de cloridrato de yonkenafil, método de preparação e composição e uso da mesma | |
| GB201500638D0 (en) | Scaffold fitting means and method of use thereof | |
| HUE055891T2 (hu) | A gonadotropint felszabadító hormon (GNRH) receptor antagonista kristályos formája és annak elõállítási módja | |
| HUE050459T2 (hu) | Androgénreceptor-gátló kristályformája és annak elõállítási eljárása | |
| EP3135669A4 (en) | Oxazolidine-based compound and selective androgen receptor agonist comprising same | |
| EP3277665A4 (en) | Indole analogs as 5-oxo-ete receptor antagonists and method of use thereof | |
| GB201508694D0 (en) | Construction apparatus and method of use thereof | |
| AU2014903404A0 (en) | Receptor dimerization domain and method of use | |
| GB201403200D0 (en) | Cushion means and method of use thereof |